Ornithine Transcarbamylase Deficiency
Conditions
Keywords
Neuroimaging, MRI, Urea cycle, hyperammonemia, cognitive function, ornithine transcarbamylase deficiency
Brief summary
The purpose of this study is to use various types of MRI and cognitive testing to evaluate changes in the brain and cognitive function that occur in subjects with ornithine transcarbamylase deficiency (OTCD) relative to healthy individuals
Detailed description
The overall goal of this project is to characterize metabolic, structural and cognitive changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of executive function measures to validate biomarkers for the effect of HA and its treatment on the brain. The investigators will measure gln and mI in blood and brain (using 1H MRS) in affected participants, and mI in brain in controls, fractional anisotropy as a measure of white matter microstructural damage (by DTI) and brain activation pathways alterations with tasks probing working memory (fMRI). As a secondary outcome measure, the investigators will correlate the findings from neuroimaging with cognitive functioning. This protocol is based on the previous 5104 protocol, now includes children to evaluate the age and stage of disease on these indices in a cohort that is undergoing important developmental events against an age matched typically developing cohort.
Interventions
1H MRS, DTI, FMRI
Behavioral testing
Sponsors
Study design
Eligibility
Inclusion criteria
Subject inclusion criteria: 1. Patients with OTCD; 2. Age range: 7-60 years 3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices) 4. Subject has a documented full scale IQ \> 70 Control participant inclusion criteria: 1. Healthy males and females without metabolic disease aged 7-60 years 2. Subject has a documented full scale IQ \> 70
Exclusion criteria
Subject
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of Glutamine and Myoinositol | Baseline | Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point. Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM). |
| Functional Connectivity of Assessed by Resting-state fMRI | Baseline | Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO). |
| Fractional Anisotropy Assessed Using DTI | Baseline | Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neuropsychological Assessment | Baseline | Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Subjects With OTCD males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing | 20 |
| Healthy Controls males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing | 27 |
| Total | 47 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Physician Decision | 0 | 2 |
Baseline characteristics
| Characteristic | Subjects With OTCD | Healthy Controls | Total |
|---|---|---|---|
| Age, Continuous | 30.3 years STANDARD_DEVIATION 19.4 | 25.8 years STANDARD_DEVIATION 14.6 | 28.05 years STANDARD_DEVIATION 17.02 |
| Sex: Female, Male Female | 17 Participants | 19 Participants | 36 Participants |
| Sex: Female, Male Male | 3 Participants | 8 Participants | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 20 | 0 / 29 |
| serious Total, serious adverse events | 0 / 20 | 0 / 29 |
Outcome results
Concentration of Glutamine and Myoinositol
Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point. Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).
Time frame: Baseline
Population: Two OTCD patients and one healthy control were excluded due to excessive head motion.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With OTCD | Concentration of Glutamine and Myoinositol | Concentration of glutamine in PWM | 2.61 mM | Standard Deviation 1.07 |
| Subjects With OTCD | Concentration of Glutamine and Myoinositol | Concentration of myoinositol in PWM | 2.23 mM | Standard Deviation 0.84 |
| Subjects With OTCD | Concentration of Glutamine and Myoinositol | Concentration of glutamine in PCGM | 5.22 mM | Standard Deviation 1.7 |
| Subjects With OTCD | Concentration of Glutamine and Myoinositol | Concentration of myoinositol in PCGM | 3.80 mM | Standard Deviation 0.8 |
| Healthy Controls | Concentration of Glutamine and Myoinositol | Concentration of myoinositol in PCGM | 4.37 mM | Standard Deviation 0.46 |
| Healthy Controls | Concentration of Glutamine and Myoinositol | Concentration of glutamine in PWM | 1.66 mM | Standard Deviation 0.93 |
| Healthy Controls | Concentration of Glutamine and Myoinositol | Concentration of glutamine in PCGM | 3.62 mM | Standard Deviation 0.91 |
| Healthy Controls | Concentration of Glutamine and Myoinositol | Concentration of myoinositol in PWM | 2.69 mM | Standard Deviation 0.48 |
Fractional Anisotropy Assessed Using DTI
Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Subjects With OTCD | Fractional Anisotropy Assessed Using DTI | 0.25 units on a scale | Standard Deviation 0.003 |
| Healthy Controls | Fractional Anisotropy Assessed Using DTI | 0.3 units on a scale | Standard Deviation 0.008 |
Functional Connectivity of Assessed by Resting-state fMRI
Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).
Time frame: Baseline
Population: Resting state data was not acquired for several of our participants (7 controls and 4 patients). Furthermore, 3 OTCD patients were excluded from the analyses due to excessive head motion.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & left IPL connectivity | -0.86 z-scores | Standard Deviation 0.7 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & PCC connectivity | -0.10 z-scores | Standard Deviation 0.7 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & right IPL connectivity | -0.26 z-scores | Standard Deviation 0.53 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: PCC & left IPL connectivity | 0.69 z-scores | Standard Deviation 0.63 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: PCC & right IPL connectivity | 0.66 z-scores | Standard Deviation 0.42 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | DMN: left IPL & right IPL connectivity | 0.75 z-scores | Standard Deviation 0.69 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & left aI/fO connectivity | 0.19 z-scores | Standard Deviation 0.39 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & left SFG connectivity | 0.28 z-scores | Standard Deviation 0.35 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & right aI/fO connectivity | 0.21 z-scores | Standard Deviation 0.3 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & right SFG connectivity | 0.29 z-scores | Standard Deviation 0.37 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & left SFG connectivity | 0.10 z-scores | Standard Deviation 0.35 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & right aI/fO connectivity | 0.71 z-scores | Standard Deviation 0.43 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & right SFG connectivity | 0.05 z-scores | Standard Deviation 0.33 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left SFG & right SFG connectivity | 0.70 z-scores | Standard Deviation 0.43 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: right aI/fO & left SFG connectivity | 0.02 z-scores | Standard Deviation 0.22 |
| Subjects With OTCD | Functional Connectivity of Assessed by Resting-state fMRI | SMN: right aI/fO & right SFG connectivity | 0.04 z-scores | Standard Deviation 0.26 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: right aI/fO & right SFG connectivity | 0.27 z-scores | Standard Deviation 0.35 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & left IPL connectivity | 0.18 z-scores | Standard Deviation 0.3 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & right aI/fO connectivity | 0.44 z-scores | Standard Deviation 0.29 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & PCC connectivity | 0.12 z-scores | Standard Deviation 0.4 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & right SFG connectivity | 0.11 z-scores | Standard Deviation 0.33 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: ACC/mPFC & right IPL connectivity | 0.07 z-scores | Standard Deviation 0.34 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & right SFG connectivity | 0.59 z-scores | Standard Deviation 0.23 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: PCC & left IPL connectivity | 0.69 z-scores | Standard Deviation 0.31 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: right aI/fO & left SFG connectivity | 0.25 z-scores | Standard Deviation 0.21 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: PCC & right IPL connectivity | 0.64 z-scores | Standard Deviation 0.3 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & left SFG connectivity | 0.22 z-scores | Standard Deviation 0.38 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | DMN: left IPL & right IPL connectivity | 0.70 z-scores | Standard Deviation 0.34 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left SFG & right SFG connectivity | 0.68 z-scores | Standard Deviation 0.28 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & left aI/fO connectivity | 0.28 z-scores | Standard Deviation 0.41 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: left aI/fO & right aI/fO connectivity | 0.80 z-scores | Standard Deviation 0.35 |
| Healthy Controls | Functional Connectivity of Assessed by Resting-state fMRI | SMN: ACC & left SFG connectivity | 0.44 z-scores | Standard Deviation 0.29 |
Neuropsychological Assessment
Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.
Time frame: Baseline
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With OTCD | Neuropsychological Assessment | WASI - Full IQ | 103.28 units on a scale | Standard Deviation 14.02 |
| Subjects With OTCD | Neuropsychological Assessment | Brief - Behavioral Regulation Index (BRI) | 55.59 units on a scale | Standard Deviation 9.49 |
| Subjects With OTCD | Neuropsychological Assessment | WASI - Performance IQ | 98.5 units on a scale | Standard Deviation 13.14 |
| Subjects With OTCD | Neuropsychological Assessment | Brief - Metacognition Index (MI) | 60.45 units on a scale | Standard Deviation 11.75 |
| Subjects With OTCD | Neuropsychological Assessment | Trails - Composite | 48 units on a scale | Standard Deviation 15 |
| Subjects With OTCD | Neuropsychological Assessment | Brief - Global Executive Composite Score (GEC) | 59.05 units on a scale | Standard Deviation 10.37 |
| Subjects With OTCD | Neuropsychological Assessment | WASI - Verbal IQ | 107.33 units on a scale | Standard Deviation 14.52 |
| Healthy Controls | Neuropsychological Assessment | Brief - Global Executive Composite Score (GEC) | 46.88 units on a scale | Standard Deviation 7.67 |
| Healthy Controls | Neuropsychological Assessment | WASI - Verbal IQ | 107.77 units on a scale | Standard Deviation 18.59 |
| Healthy Controls | Neuropsychological Assessment | WASI - Performance IQ | 112.59 units on a scale | Standard Deviation 14.54 |
| Healthy Controls | Neuropsychological Assessment | WASI - Full IQ | 111.22 units on a scale | Standard Deviation 16.89 |
| Healthy Controls | Neuropsychological Assessment | Trails - Composite | 47 units on a scale | Standard Deviation 12 |
| Healthy Controls | Neuropsychological Assessment | Brief - Behavioral Regulation Index (BRI) | 46.73 units on a scale | Standard Deviation 8.9 |
| Healthy Controls | Neuropsychological Assessment | Brief - Metacognition Index (MI) | 47.38 units on a scale | Standard Deviation 8.22 |